Vosevi

FDA

• Treatment of adult patients with chronic HCV infection without cirrhosis or compensated cirrhosis (Child-Pugh A) who have:
  • Genotype 1, 2, 3, 4, 5 or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor
  • Genotype 1a or 3 infection and have been previously treated with sofosbuvir without an NS5A inhibitor